Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2024 / Articles / Sep / Driving the Future of Biopharma
Business & Regulation Business Practice Standards & Regulation Regulation & Standards

Driving the Future of Biopharma

Biopharma companies procrastinating on sustainability measures risk falling behind, according to Cytiva’ Global Biopharma Sustainability Review

By Rob Coker 10/01/2024 1 min read

Share

Cytiva has released its 2024 Global Biopharma Sustainability Review, highlighting the increasing importance of sustainability initiatives to biopharma manufacturers. A survey of 800 industry professionals from 18 countries indicates that sustainability has moved from a peripheral concern to a central focus, with 62 percent of respondents suggesting that sustainability will be a key driver of success in the next five years.

Major influences driving the sustainability-focused trend include regulatory pressures, stakeholder expectations, and the potential of good sustainability practices in enhancing reputation and attracting talent. The major headache? Quantifying return on sustainability investment. In fact, 76 percent of the companies surveyed expressed concern with how their efforts will be measured and what impact they will have, while others conceded that tracking and reporting on accurate sustainability metrics will be a challenge – especially given complex supply chains and the need for advanced technologies.

Collaboration will likely be key, according to the report; here, the harmonization of industry standards and best practices should generate new ideas for the measurement – and improvement – of these metrics. Additionally, the report advocates for sustainability being embedded into corporate strategy.

The potential benefits of successful integration into everyday operations, the report concludes, will bring environmental benefits, as well as increased revenues and profitability. And as sustainability becomes a differentiator in the market, companies that lag in this area risk falling behind their proactive competitors.

According to Cytiva’s Head of Sustainability and Corporate Responsibility, Emmanuel Abate, “These findings highlight where we as an industry must collaborate and push for better progress and prove the benefits of delivering on sustainability targets to employees, customers, and investors – both current and future.”

The full report is available on Cytiva’s website.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

Rob Coker

Following a Bachelor’s degree in English Literature and a Master’s in Creative Writing, I entered the world of publishing as a proofreader, working my way up to editor. The career so far has taken me to some amazing places, and I’m excited to see where I can go with Texere and The Medicine Maker.

More Articles by Rob Coker

False

Advertisement

Recommended

False

Related Content

What Trump’s Latest Moves Mean for the Industry
Business Practice Standards & Regulation Trends & Forecasts Bioprocessing - Upstream & Downstream
What Trump’s Latest Moves Mean for the Industry

May 27, 2025

6 min read

Audrey Greenberg’s latest insight on US-based manufacturing, Trump’s “Administration for A Healthy America”, and an ever-shifting regulatory environment.

Big Bad Pharma?
Business Practice Trends & Forecasts
Big Bad Pharma?

December 1, 2014

0 min read

The Ebola media frenzy has reminded the public how selfish our industry is. But, somehow, that doesn’t sound quite right...

Access All Areas
Business Practice Trends & Forecasts
Access All Areas

December 1, 2014

0 min read

The 2014 Access to Medicine index shows progress – but companies remain “conservative”

Care to ‘Patent Dance’?
Business Practice Trends & Forecasts
Care to ‘Patent Dance’?

December 1, 2014

0 min read

Amgen accuses Sandoz of snubbing its advances in a complex biosimilar dispute

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.